Metabolic and hormonal signatures in pre-manifest and manifest Huntington's disease patients

Frontiers in Physiology

Volumn 5 JUN, Issue , 2014, Pages

  Wang, Rui ^a   Ross, Christopher A ^b   Cai, Huan ^a   Cong, Wei Na ^a   Daimon, Caitlin M ^a   Carlson, Olga D ^a   Egan, Josephine M ^a   Siddiqui, Sana ^a   Maudsley, Stuart ^c   Martin, Bronwen ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Huntington's disease; lipids; metabolic hormones; peripheral energy metabolism; pre manifest

Indexed keywords

ADENINE; AMYLIN; C REACTIVE PROTEIN; CYTOKINE; CYTOSINE; GHRELIN; GLUCAGON; GROWTH FACTOR; GROWTH HORMONE; GUANINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROLACTIN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; ENERGY METABOLISM; FAMILIAL DISEASE; FEMALE; GENETIC SCREENING; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; HUNTINGTON CHOREA; LIPID BLOOD LEVEL; MALE; MIDDLE AGED; SIGNAL TRANSDUCTION; TRINUCLEOTIDE REPEAT;

EID: 84904393173     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2014.00231     Document Type: Article

References (71)

1. Andreassen, O. A., Dedeoglu, A., Stanojevic, V., Hughes, D. B., Browne, S. E., Leech, C. A., et al. (2002). Huntington's disease of the endocrine pancreas: insulin deficiency and diabetes mellitus due to impaired insulin gene expression. Neurobiol. Dis. 11, 410-424. doi: 10.1006/nbdi.2002.0562
2. Auffret, J., Viengchareun, S., Carre, N., Denis, R. G., Magnan, C., Marie, P. Y., et al. (2012). Beige differentiation of adipose depots in mice lacking prolactin receptor protects against high-fat-diet-induced obesity. FASEB J. 26, 3728-3737. doi: 10.1096/fj.12-204958
3. Aziz, N. A., Pijl, H., Frolich, M., Snel, M., Streefland, T. C., Roelfsema, F., et al. (2010a). Systemic energy homeostasis in Huntington's disease patients. J. Neurol. Neurosurg. Psychiatry 81, 1233-1237. doi: 10.1136/jnnp.2009.191833
4. Aziz, N. A., Pijl, H., Frolich, M., Van Der Graaf, A. W., Roelfsema, F., and Roos, R. A. (2010b). Leptin secretion rate increases with higher CAG repeat number in Huntington's disease patients. Clin. Endocrinol. (Oxf). 73, 206-211. doi: 10.1111/j.1365-2265.2009.03661.x
5. Balbach, L., Wallaschofski, H., Volzke, H., Nauck, M., Dorr, M., and Haring, R. (2013). Serum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes? BMC Endocr. Disord. 13:12. doi: 10.1186/1472-6823-13-12
6. Ballantyne, G. H., Gumbs, A., and Modlin, I. M. (2005). Changes in insulin resistance following bariatric surgery and the adipoinsular axis: role of the adipocytokines, leptin, adiponectin and resistin. Obes. Surg. 15, 692-699. doi: 10.1381/0960892053923789
7. Boesgaard, T. W., Nielsen, T. T., Josefsen, K., Hansen, T., Jørgensen, T., Pedersen, O., et al. (2009). Huntington's disease does not appear to increase the risk of diabetes mellitus. J. Neuroendocrinol. 21, 770-776. doi: 10.1111/j.1365-2826.2009.01898.x
8. Burke, K. A., Yates, E. A., and Legleiter, J. (2013). Amyloid-forming proteins alter the local mechanical properties of lipid membranes. Biochemistry 52, 808-817. doi: 10.1021/bi301070v
9. Butler, P. C., Chou, J., Carter, W. B., Wang, Y. N., Bu, B. H., Chang, D., et al. (1990). Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. Diabetes 39, 752-756. doi: 10.2337/diab.39.6.752
10. Cai, H., Cong, W. N., Ji, S., Rothman, S., Maudsley, S., and Martin, B. (2012). Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disorders. Curr. Alzheimer Res. 9, 5-17. doi: 10.2174/156720512799015064
11. Chadwick, W., Magnus, T., Martin, B., Keselman, A., Mattson, M. P., and Maudsley, S. (2008). Targeting TNF-alpha receptors for neurotherapeutics. Trends Neurosci. 31, 504-511. doi: 10.1016/j.tins.2008.07.005
12. Chapter, M. C., White, C. M., Deridder, A., Chadwick, W., Martin, B., and Maudsley, S. (2010). Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies. Pharmacol. Ther. 125, 39-54. doi: 10.1016/j.pharmthera.2009.07.006
13. Chirico, V., Cannavò, S., Lacquaniti, A., Salpietro, V., Mandolfino, M., Romeo, P. D., et al. (2013). Prolactin in obese children: a bridge between inflammation and metabolic-endocrine dysfunction. Clin. Endocrinol. 79, 537-544. doi: 10.1111/cen.12183
14. Dietschy, J. M., and Turley, S. D. (2004). Thematic review series: brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J. Lipid Res. 45, 1375-1397. doi: 10.1194/jlr.R400004-JLR200
15. Driscoll, I., Martin, B., An, Y., Maudsley, S., Ferrucci, L., Mattson, M. P., et al. (2012). Plasma BDNF is associated with age-related white matter atrophy but not with cognitive function in older, non-demented adults. PLoS ONE 7:e35217. doi: 10.1371/journal.pone.0035217
16. Evans, R. M., Emsley, C. L., Gao, S., Sahota, A., Hall, K. S., Farlow, M. R., et al. (2000). Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans. Neurology 54, 240-242. doi: 10.1212/WNL.54.1.240
17. Fanne, R. A., Nassar, T., Heyman, S. N., Hijazi, N., and Higazi, A. A. (2011a). Insulin and glucagon share the same mechanism of neuroprotection in diabetic rats: role of glutamate. Am. J. Physiol. Regul. Integr. Comp. Physiol. 301, R668-R673. doi: 10.1152/ajpregu.00058.2011
18. Fanne, R. A., Nassar, T., Mazuz, A., Waked, O., Heyman, S. N., Hijazi, N., et al. (2011b). Neuroprotection by glucagon: role of gluconeogenesis. J. Neurosurg. 114, 85-91. doi: 10.3171/2010.4.JNS10263
19. Gavrila, A., Chan, J. L., Yiannakouris, N., Kontogianni, M., Miller, L. C., Orlova, C., et al. (2003). Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies. J. Clin. Endocrinol. Metab. 88, 4823-4831. doi: 10.1210/jc.2003-030214
20. Gedulin, B. R., Jodka, C. M., Herrmann, K., and Young, A. A. (2006). Role of endogenous amylin in glucagon secretion and gastric emptying in rats demonstrated with the selective antagonist, AC187. Regul. Pept. 137, 121-127. doi: 10.1016/j.regpep.2006.06.004
21. Gerardo-Gettens, T., Moore, B. J., Stern, J. S., and Horwitz, B. A. (1989). Prolactin stimulates food intake in a dose-dependent manner. Am. J. Physiol. 256, R276-R280.
22. Golden, E., Emiliano, A., Maudsley, S., Windham, B. G., Carlson, O. D., Egan, J. M., et al. (2010). Circulating brain-derived neurotrophic factor and indices of metabolic and cardiovascular health: data from the Baltimore longitudinal study of aging. PLoS ONE 5:e10099. doi: 10.1371/journal.pone.0010099
23. Goodman, A. O., and Barker, R. A. (2011). Body composition in premanifest Huntington's disease reveals lower bone density compared to controls. PLoS Curr. 3:RRN1214. doi: 10.1371/currents.RRN1214
24. Hayden, M. R., Paul, M., Vinik, A. I., and Beighton, P. (1977). Impaired prolactin release in huntington's chorea: evidence for dopaminergic excess. Lancet 310, 423-426. doi: 10.1016/S0140-6736(77)90608-0
25. Hering, H., Lin, C. C., and Sheng, M. (2003). Lipid rafts in the maintenance of synapses, dendritic spines, and surface AMPA receptor stability. J. Neurosci. 23, 3262-3271.
26. Hurlbert, M. S., Zhou, W., Wasmeier, C., Kaddis, F. G., Hutton, J. C., and Freed, C. R. (1999). Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. Diabetes 48, 649-651. doi: 10.2337/diabetes.48.3.649
27. Johnson, J. B., Summer, W., Cutler, R. G., Martin, B., Hyun, D. H., Dixit, V. D., et al. (2007). Alternate day calorie restriction improves clinical findings and reduces markers of oxidative stress and inflammation in overweight adults with moderate asthma. Free Radic. Biol. Med. 42, 665-674. doi: 10.1016/j.freeradbiomed.2006.12.005
28. Kadowaki, T., Yamauchi, T., Kubota, N., Hara, K., Ueki, K., and Tobe, K. (2006). Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J. Clin. Invest. 116, 1784-1792. doi: 10.1172/JCI29126
29. Kaushik, S., Rodriguez-Navarro, J. A., Arias, E., Kiffin, R., Sahu, S., Schwartz, G. J., et al. (2011). Autophagy in hypothalamic AgRP neurons regulates food intake and energy balance. Cell Metab. 14, 173-183. doi: 10.1016/j.cmet.2011.06.008
30. Koda, J. E., Fineman, M., Rink, T. J., Dailey, G. E., Muchmore, D. B., and Linarelli, L. G. (1992). Amylin concentrations and glucose control. Lancet 339, 1179-1180. doi: 10.1016/0140-6736(92)90785-2
31. Kolaczynski, J. W., Considine, R. V., Ohannesian, J., Marco, C., Opentanova, I., Nyce, M. R., et al. (1996). Responses of leptin to short-term fasting and refeeding in humans: a link with ketogenesis but not ketones themselves. Diabetes 45, 1511-1515. doi: 10.2337/diab.45.11.1511
32. Kremer, H. P., Roos, R. A., Frolich, M., Radder, J. K., Nieuwenhuijzen Kruseman, A. C., Van Der Velde, A., et al. (1989). Endocrine functions in Huntington's disease. A two-and-a-half years follow-up study. J. Neurol. Sci. 90, 335-344. doi: 10.1016/0022-510X(89)90120-2
33. Lagrand, W. K., Visser, C. A., Hermens, W. T., Niessen, H. W., Verheugt, F. W., Wolbink, G. J., et al. (1999). C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation 100, 96-102. doi: 10.1161/01.CIR.100.1.96
34. Leoni, V., Mariotti, C., Nanetti, L., Salvatore, E., Squitieri, F., Bentivoglio, A. R., et al. (2011). Whole body cholesterol metabolism is impaired in Huntington's disease. Neurosci. Lett. 494, 245-249. doi: 10.1016/j.neulet.2011.03.025
35. Licastro, F., Pedrini, S., Caputo, L., Annoni, G., Davis, L. J., Ferri, C., et al. (2000). Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? J. Neuroimmunol. 103, 97-102. doi: 10.1016/S0165-5728(99)00226-X
36. Lorenzo, A., Razzaboni, B., Weir, G. C., and Yankner, B. A. (1994). Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 368, 756-760. doi: 10.1038/368756a0
37. Macdonald, I. A. (1997). Amylin and the gastrointestinal tract. Diabet. Med. 14(Suppl. 2), S24-S28. doi: 10.1002/(SICI)1096-9136(199706)14:2+3.0.CO;2-M.
38. Maffei, M., Halaas, J., Ravussin, E., Pratley, R. E., Lee, G. H., Zhang, Y., et al. (1995). Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat. Med. 1, 1155-1161. doi: 10.1038/nm1195-1155
39. Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., et al. (1996). Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493-506. doi: 10.1016/S0092-8674(00)81369-0
40. Markianos, M., Panas, M., Kalfakis, N., and Vassilopoulos, D. (2008). Low plasma total cholesterol in patients with Huntington's disease and first-degree relatives. Mol. Genet. Metab. 93, 341-346. doi: 10.1016/j.ymgme.2007.10.002
41. Martin, B., Chadwick, W., Cong, W. N., Pantaleo, N., Daimon, C. M., Golden, E. J., et al. (2012). Euglycemic agent-mediated hypothalamic transcriptomic manipulation in the N171-82Q model of Huntington disease is related to their physiological efficacy. J. Biol. Chem. 287, 31766-31782. doi: 10.1074/jbc.M112.387316
42. Martin, B., De Maturana, R. L., Brenneman, R., Walent, T., Mattson, M. P., and Maudsley, S. (2005). Class II G protein-coupled receptors and their ligands in neuronal function and protection. Neuromolecular Med. 7, 3-36. doi: 10.1385/NMM:7:1-2:003
43. Martin, B., Golden, E., Carlson, O. D., Pistell, P., Zhou, J., Kim, W., et al. (2009). Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease. Diabetes 58, 318-328. doi: 10.2337/db08-0799
44. Martin, B., Golden, E., Keselman, A., Stone, M., Mattson, M. P., Egan, J. M., et al. (2008). Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body. Histol. Histopathol. 23, 237-250.
45. Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., and Turner, R. C. (1985). Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412-419. doi: 10.1007/BF00280883
46. Mauch, D. H., Nägler, K., Schumacher, S., Göritz, C., Müller, E.-C., Otto, A., et al. (2001). CNS synaptogenesis promoted by glia-derived cholesterol. Science 294, 1354-1357. doi: 10.1126/science.294.5545.1354
47. Moreno-Gonzalez, I., and Soto, C. (2011). Misfolded protein aggregates: mechanisms, structures and potential for disease transmission. Semin. Cell Dev. Biol. 22, 482-487. doi: 10.1016/j.semcdb.2011.04.002
48. Phan, J., Hickey, M. A., Zhang, P., Chesselet, M. F., and Reue, K. (2009). Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse models. Hum. Mol. Genet. 18, 1006-1016. doi: 10.1093/hmg/ddn428
49. Phelps, C. J. (1994). Pituitary hormones as neurotrophic signals: anomalous hypophysiotrophic neuron differentiation in hypopituitary dwarf mice. Proc. Soc. Exp. Biol. Med. 206, 6-23. doi: 10.3181/00379727-206-43719
50. Phelps, C. J., and Hurley, D. L. (1999). Pituitary hormones as neurotrophic signals: update on hypothalamic differentiation in genetic models of altered feedback. Proc. Soc. Exp. Biol. Med. 222, 39-58. doi: 10.1111/j.1525-1373.1999.09994.x
51. Pittner, R. A., Albrandt, K., Beaumont, K., Gaeta, L. S., Koda, J. E., Moore, C. X., et al. (1994). Molecular physiology of amylin. J. Cell. Biochem. 55(Suppl.), 19-28. doi: 10.1002/jcb.240550004
52. Podolsky, S., and Leopold, N. A. (1977). Abnormal glucose tolerance and arginine tolerance tests in Huntington's disease. Gerontology 23, 55-63. doi: 10.1159/000212174
53. Podolsky, S., Leopold, N. A., and Sax, D. S. (1972). Increased frequency of diabetes mellitus in patients with Huntington's chorea. Lancet 1, 1356-1358. doi: 10.1016/S0140-6736(72)91092-6
54. Popovic, V., Svetel, M., Djurovic, M., Petrovic, S., Doknic, M., Pekic, S., et al. (2004). Circulating and cerebrospinal fluid ghrelin and leptin: potential role in altered body weight in Huntington's disease. Eur. J. Endocrinol. 151, 451-455. doi: 10.1530/eje.0.1510451
55. Potes, C. S., Boyle, C. N., Wookey, P. J., Riediger, T., and Lutz, T. A. (2012). Involvement of the extracellular signal-regulated kinase 1/2 signaling pathway in amylin's eating inhibitory effect. Am. J. Physiol. Regul. Integr. Comp. Physiol. 302, R340-351. doi: 10.1152/ajpregu.00380.2011
56. Quan, G., Xie, C., Dietschy, J. M., and Turley, S. D. (2003). Ontogenesis and regulation of cholesterol metabolism in the central nervous system of the mouse. Dev. Brain Res. 146, 87-98. doi: 10.1016/j.devbrainres.2003.09.015
57. Quist, A., Doudevski, I., Lin, H., Azimova, R., Ng, D., Frangione, B., et al. (2005). Amyloid ion channels: a common structural link for protein-misfolding disease. Proc. Natl. Acad. Sci. U.S.A. 102, 10427-10432. doi: 10.1073/pnas.0502066102
58. Redelman, D., Welniak, L. A., Taub, D., and Murphy, W. J. (2008). Neuroendocrine hormones such as growth hormone and prolactin are integral members of the immunological cytokine network. Cell. Immunol. 252, 111-121. doi: 10.1016/j.cellimm.2007.12.003
59. Ross, C. A., and Tabrizi, S. J. (2011). Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 10, 83-98. doi: 10.1016/S1474-4422(10)70245-3
60. Schäffler, A., Binart, N., Schölmerich, J., and Büchler, C. (2005). Hypothesis paper Brain talks with fat - evidence for a hypothalamic-pituitary-adipose axis? Neuropeptides 39, 363-367. doi: 10.1016/j.npep.2005.06.003
61. Stoy, N., Mackay, G. M., Forrest, C. M., Christofides, J., Egerton, M., Stone, T. W., et al. (2005). Tryptophan metabolism and oxidative stress in patients with Huntington's disease. J. Neurochem. 93, 611-623. doi: 10.1111/j.1471-4159.2005.03070.x
62. Stranahan, A. M., Martin, B., and Maudsley, S. (2012). Anti-inflammatory effects of physical activity in relationship to improved cognitive status in humans and mouse models of Alzheimer's disease. Curr. Alzheimer Res. 9, 86-92. doi: 10.2174/156720512799015019
63. Torner, L., Karg, S., Blume, A., Kandasamy, M., Kuhn, H. G., Winkler, J., et al. (2009). Prolactin prevents chronic stress-induced decrease of adult hippocampal neurogenesis and promotes neuronal fate. J. Neurosci. 29, 1826-1833. doi: 10.1523/JNEUROSCI.3178-08.2009
64. Valenza, M., Rigamonti, D., Goffredo, D., Zuccato, C., Fenu, S., Jamot, L., et al. (2005). Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. J. Neurosci. 25, 9932-9939. doi: 10.1523/JNEUROSCI.3355-05.2005
65. Van Der Burg, J. M. M., Björkqvist, M., and Brundin, P. (2009). Beyond the brain: widespread pathology in Huntington's disease. Lancet Neurol. 8, 765-774. doi: 10.1016/S1474-4422(09)70178-4
66. Walker, F. O. (2007). Huntington's disease. Lancet 369, 218-228. doi: 10.1016/S0140-6736(07)60111-1
67. Weir, D. W., Sturrock, A., and Leavitt, B. R. (2011). Development of biomarkers for Huntington's disease. Lancet Neurol. 10, 573-590. doi: 10.1016/S1474-4422(11)70070-9
68. Westermark, G. T., and Westermark, P. (2011). Localized amyloids important in diseases outside the brain-lessons from the islets of Langerhans and the thoracic aorta. FEBS J. 278, 3918-3929. doi: 10.1111/j.1742-4658.2011.08298.x
69. Wood, N. I., Sawiak, S. J., Buonincontri, G., Niu, Y., Kane, A. D., Carpenter, T. A., et al. (2012). Direct evidence of progressive cardiac dysfunction in a transgenic mouse model of Huntington's disease. J. Huntingtons Dis. 1, 57-64. doi: 10.3233/JHD-2012-120004
70. Yamamura, M., Yamada, Y., Momita, S., Kamihira, S., and Tomonaga, M. (1998). Circulating interleukin-6 levels are elevated in adult T-cell leukaemia/lymphoma patients and correlate with adverse clinical features and survival. Br. J. Haematol. 100, 129-134. doi: 10.1046/j.1365-2141.1998.00538.x
71. Ye, J. M., Lim-Fraser, M., Cooney, G. J., Cooper, G. J., Iglesias, M. A., Watson, D. G., et al. (2001). Evidence that amylin stimulates lipolysis in vivo: a possible mediator of induced insulin resistance. Am. J. Physiol. Endocrinol. Metab. 280, E562-E569.